Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer
Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving everolimus before surgery may make the tumor smaller and
reduce the amount of normal tissue that needs to be removed.
PURPOSE: This randomized phase II trial is studying the side effects and how well everolimus
works in treating patients with newly diagnosed localized prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Case Comprehensive Cancer Center Jorge A. Garcia, MD